Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer's Trial Results, Says BMO Capital

Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company (NYSE:LLY). According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the market predicts, possibly as early as the fourth quarter of 2025.

According to BMO Capital’s analysis, even with a low alpha spend, this intermediate review may show statistical significance. The firm notes that a favorable readout might enhance public perception of beta-amyloid Alzheimer’s treatment and possibly increase its long-term market potential to include patients whose disease has not yet progressed.

In the best-case scenario, BMO Capital predicts that Eli Lilly’s stock might rise by about 7% due to positive interim results.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.